Cited 9 times in
Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 안중배 | - |
dc.date.accessioned | 2022-11-24T01:00:05Z | - |
dc.date.available | 2022-11-24T01:00:05Z | - |
dc.date.issued | 2021-11 | - |
dc.identifier.issn | 1347-9032 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/191121 | - |
dc.description.abstract | The phase III AXEPT study showed the noninferiority of modified capecitabine plus irinotecan (mXELIRI) with or without bevacizumab relative to fluorouracil, leucovorin, and irinotecan (FOLFIRI) with or without bevacizumab as a second-line treatment for metastatic colorectal cancer. We evaluated the associations between the UGT1A1 genotype linked to adverse events-caused by irinotecan-and the efficacy and safety of mXELIRI and FOLFIRI. The UGT1A1 genotype was prospectively determined and patients were categorized into three groups according to WT (*1/*1), single heterozygous (SH; *28/*1 or *6/*1), and double heterozygous or homozygous (DHH; *28/*28, *6/*6, or *28/*6). Overall survival (OS), progression-free survival, response rate, and safety were assessed. The UGT1A1 genotype was available in all 650 randomized patients (WT, 309 [47.5%]; SH, 291 [44.8%]; DHH, 50 [7.7%]). The median OS was 15.9, 17.7, and 10.6 months in the WT, SH, and DHH groups, respectively, with an adjusted hazard ratio (HR) of 1.53 (95% confidence interval [CI], 1.12-2.09; P = .008) for DHH vs WT or SH. The median OS in the mXELIRI and FOLFIRI arms was 18.1 vs 14.3 months (HR 0.80; 95% CI, 0.62-1.03) in the WT group, 16.3 vs 18.3 months (HR 1.04; 95% CI, 0.79-1.36) in the SH group, and 13.0 vs 9.1 months (HR 0.71; 95% CI, 0.39-1.31) in the DHH group, respectively. Modified capecitabine plus irinotecan with or without bevacizumab could be a standard second-line chemotherapy in terms of efficacy and safety regardless of the UGT1A1 genotype. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Wiley Publishing on behalf of the Japanese Cancer Association | - |
dc.relation.isPartOf | CANCER SCIENCE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / therapeutic use* | - |
dc.subject.MESH | Bevacizumab / therapeutic use | - |
dc.subject.MESH | Camptothecin / adverse effects | - |
dc.subject.MESH | Camptothecin / analogs & derivatives* | - |
dc.subject.MESH | Camptothecin / therapeutic use | - |
dc.subject.MESH | Colorectal Neoplasms / drug therapy* | - |
dc.subject.MESH | Colorectal Neoplasms / genetics | - |
dc.subject.MESH | Colorectal Neoplasms / mortality | - |
dc.subject.MESH | Colorectal Neoplasms / pathology | - |
dc.subject.MESH | Confidence Intervals | - |
dc.subject.MESH | Deoxycytidine / adverse effects | - |
dc.subject.MESH | Deoxycytidine / analogs & derivatives* | - |
dc.subject.MESH | Deoxycytidine / therapeutic use | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil / adverse effects | - |
dc.subject.MESH | Fluorouracil / analogs & derivatives* | - |
dc.subject.MESH | Fluorouracil / therapeutic use | - |
dc.subject.MESH | Genotype* | - |
dc.subject.MESH | Glucuronosyltransferase / genetics* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Leucovorin / adverse effects | - |
dc.subject.MESH | Leucovorin / therapeutic use | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Progression-Free Survival | - |
dc.subject.MESH | Topoisomerase I Inhibitors / adverse effects | - |
dc.subject.MESH | Topoisomerase I Inhibitors / therapeutic use* | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Young Adult | - |
dc.title | Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Satoru Iwasa | - |
dc.contributor.googleauthor | Kei Muro | - |
dc.contributor.googleauthor | Satoshi Morita | - |
dc.contributor.googleauthor | Young Suk Park | - |
dc.contributor.googleauthor | Masato Nakamura | - |
dc.contributor.googleauthor | Masahito Kotaka | - |
dc.contributor.googleauthor | Tomohiro Nishina | - |
dc.contributor.googleauthor | Hiroshi Matsuoka | - |
dc.contributor.googleauthor | Joong Bae Ahn | - |
dc.contributor.googleauthor | Keun-Wook Lee | - |
dc.contributor.googleauthor | Yong Sang Hong | - |
dc.contributor.googleauthor | Sae Won Han | - |
dc.contributor.googleauthor | Sang-Hee Cho | - |
dc.contributor.googleauthor | Dong-Sheng Zhang | - |
dc.contributor.googleauthor | Wei-Jia Fang | - |
dc.contributor.googleauthor | Li Bai | - |
dc.contributor.googleauthor | Xiang-Lin Yuan | - |
dc.contributor.googleauthor | Ying Yuan | - |
dc.contributor.googleauthor | Yasuhide Yamada | - |
dc.contributor.googleauthor | Junichi Sakamoto | - |
dc.contributor.googleauthor | Tae Won Kim | - |
dc.identifier.doi | 10.1111/cas.15092 | - |
dc.contributor.localId | A02262 | - |
dc.relation.journalcode | J00454 | - |
dc.identifier.eissn | 1349-7006 | - |
dc.identifier.pmid | 34327766 | - |
dc.subject.keyword | UGT1A1 | - |
dc.subject.keyword | XELIRI | - |
dc.subject.keyword | capecitabine | - |
dc.subject.keyword | colorectal cancer | - |
dc.subject.keyword | irinotecan | - |
dc.contributor.alternativeName | Ahn, Joong Bae | - |
dc.contributor.affiliatedAuthor | 안중배 | - |
dc.citation.volume | 112 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 4669 | - |
dc.citation.endPage | 4678 | - |
dc.identifier.bibliographicCitation | CANCER SCIENCE, Vol.112(11) : 4669-4678, 2021-11 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.